Clinical trial
Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV…
NCT00097838 · AlphaVax, Inc., Industry · Completed
Key facts
| NCT number | NCT00097838 |
|---|---|
| Title | Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults |
| Official title | A Phase I, Dose Escalation, Safety, and Immunogenicity Trial of an Alphavirus Replicon HIV-1 Subtype C Gag Vaccine (AVX101) in Healthy HIV-1 Uninfected Adult Participants |
| Lead sponsor | AlphaVax, Inc., Industry |
| Collaborators | HIV Vaccine Trials Network National Institute of Allergy and Infectious Diseases (NIAID) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Biological, Other |
| Interventions | AVX101, placebo |
| Enrollment | 96 |
| Start date | Oct 1, 2004 |
| Primary completion | Sep 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | Dec 1, 2004 |
| Last update posted | Jul 2, 2012 |
| Countries | Botswana, South Africa, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: